Abstract
ABSTRACTThe confluence of the immunology and oncology tributaries has precipitated a biomarker turbulence that is novel to the cancer community. On the heels of reversing the dismal outcomes for numerous patients suffering from terminal disease, it has also left behind deep pools of biomarker questions – which ones, when to use them, how to use them and what cells express them – to name just a few. The tumor microenvironment, an arena potentially housing a complex mix of immune infiltrators in the midst of tumor cells, is a wildly heterogeneous terrain, one that severely challenges our single biomarker model. This article examines the recently FDA-approved biomarker assays for PD-1 therapeutics, considers the technical shortcomings of the single biomarker model, scans alternate biomarker technologies and proposes a model that may allow investigators a method to systematically address these complexities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Expert Review of Precision Medicine and Drug Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
